pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CDK4/6 · news · pharmadog
← back to CDK4/6
News · CDK4/6
17
stories
4d
Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
fiercebiotech
5d
Iambic, an AI drug discovery specialist, banks $150M in an IPO
biopharma dive
11d
AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic
fiercebiotech
27d
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
Sep 14, 26
AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
biospace
Sep 8, 26
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
biospace
Sep 8, 26
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
fiercebiotech
Sep 7, 26
Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamah
fiercebiotech
Sep 4, 26
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
fda press
Jul 16, 26
Chutes & Ladders—Cue lines up new CMO and research head
fiercebiotech
Jun 2, 26
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
biopharma dive
Jun 1, 26
#ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
endpoints
May 12, 26
Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
onclive
May 9, 26
The OncFive: Top Oncology Articles for the Week of 5/3
onclive
May 8, 26
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
onclive
May 8, 26
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
onclive
May 6, 26
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
onclive
